ClinicalTrials.gg
CompletedNCT00552240Updated Jan 27, 2014Results posted

Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)

A Phase 4 interventional study of tenofovir DF 300 mg QD and tenofovir DF 300 mg QD in HIV Infections, sponsored by Boehringer Ingelheim. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-27.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies testing nevirapine in HIV Infections — 1 open to participants now, 1 under way, none of them phase 3. Nevirapine · HIV Infections.

Enrollment
39th of 81
154 · median 142
Started
2007
with 7 others
Phase 4
15 of 82
none open now
Registered
56th of 82
by date
Lead sponsor
21 of 82
Boehringer Ingelheim

Among the 82 studies testing nevirapine in HIV Infections, this one is the 39th largest by enrollment of the 81 interventional ones that give a count, is one of 8 that started in 2007, is one of 15 in phase 4, and was the 56th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 82 studies testing nevirapine in HIV Infections is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About nevirapine

Nevirapine: first FDA approval 1996 (VIRAMUNE), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing nevirapine in HIV Infections, or all of them as a file.
02

Study summary

The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
  2. -1- infected males or females greater than or equal to 18 years of age with documented positive serology Enzyme-linked Immuno Sorbert Assay (ELISA) confirmed by Western blot
  3. No prior nucleoside reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) use of more than 10 days AND
  4. No prior use of other classes of antiretrovirals (ARVs) of more than 2 weeks duration
  5. Males with less than 400 cells/mm cubed or females with CD4+ count less than 250 cells/mm cubed
  6. NVP and ATV/r susceptibility on screening HIV-1 genotypic resistance assay
  7. Adequate renal function defined as a calculated greater than or equal to50 ml/min according to the Cockcroft-Gault formula
  8. score greater than or equal to 70 (see Appendix 10.7)
  9. Acceptable medical history, as assessed by the investigator

Exclusion criteria

Exclusion criteria:

  1. History of active drug or alcohol abuse within 2 years prior to study entry (at the investigators discretion)
  2. Hepatic cirrhosis with stage B or C hepatic impairment
  3. Female patients of who:

    have a positive serum pregnancy test at screening, are breast feeding, are planning to become pregnant, are not willing to use a barrier method of , or are not willing to use methods of contraception other than ethinyl estradiol containing oral contraceptives

  4. Laboratory parameters greater than Division of Aids (National Institute of Health, USA) (DAIDS) grade 2 (triglycerides greater than DAIDS grade 3, total cholesterol no restrictions, see Appendix 10.1)
  5. Active or C disease, defined as HBsAg-positive or Virus (HCV) RNA positive with (ALT) and aspartate aminotransferase (AST) ALT/AST greater than2.5x (ULN) (greater than DAIDS grade 1)
  6. Known to any ingredients in nevirapine or atazanavir
  7. Patients who are receiving concomitant treatments which are not permitted, as listed in Appendix 10.6
  8. Use of other medications within 30 days before study entry or during the trial
  9. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g., interferon, cyclosporin, hydroxyurea, interleukin 2, chronic treatment with prednisone)
  10. Patients with Progressive Multifocal Leukoencephalopathy (PML), visceral Kaposi's Sarcoma (KS), and/or any lymphoma
  11. Any AIDS defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at the screening visit
  12. Patients who are receiving systemic chemotherapy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Active comparator
    NVP 200mg bis indie (BID)

    after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks

    Drug: tenofovir DF 300 mg QD · Drug: emtricitabine 200 mg QD · Drug: Nevirapine 200 mg BID

  • Active comparator
    Atazanavir 300 mg QD/ritonavir 100 mg QD

    patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks

    Drug: tenofovir DF 300 mg QD · Drug: emtricitabine 200 mg QD · Drug: Atazanavir 300 mg · Drug: Ritonavir 100 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Virologic Response (VR)

    VR is defined as HIV viral load of \<50 copies/ml measured at two consecutive visits PRIOR TO Week 48 and without subsequent rebound or change of ARV therapy prior to Week 48.

    Time frame: baseline to week 48

Secondary outcomes

  1. Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm

    HIV viral load \<50 copies/ml measured at two consecutive visits UP TO Week 48 and without subsequent rebound or change of ARV therapy up to Week 48.

    Time frame: baseline to week 48

  2. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48

    HIV viral load \<50 copies/ml measured at Week 48 among observed cases on-treatment.

    Time frame: baseline to week 48

  3. Number of Participants With Virologic Success (FDA Definition)

    HIV viral load \<50 copies/ml measured in the Week 48 window whereby patients withdrawing early and patients without a Week 48 assessment are considered failures. Includes all participants in full analysis set (FAS).

    Time frame: baseline to week 48

  4. Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants

    Time to response whereby patients withdrawing early were censored after their withdrawal

    Time frame: baseline to week 48

  5. Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml

    Time frame: baseline to week 48

  6. Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response

    HIV viral load \> 50 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)

    Time frame: baseline to week 24 and week 48

  7. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 2

  8. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 4

  9. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 6

  10. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 8

  11. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 12

  12. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 24

  13. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 36

  14. Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 48

  15. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 2

  16. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 4

  17. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 6

  18. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 8

  19. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 12

  20. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 24

  21. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 36

  22. Number of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment

    Results within time windows, patients on-treatment

    Time frame: baseline to week 48

  23. Number of Patients With Virologic Rebound to >400 Copies/ml

    HIV viral load \>400 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)

    Time frame: baseline to week 48

  24. AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death

    AIDS defining illnesses include: Aspergillosis, Bartonellosis, Candidiasis, Cervical cancer, Chagas disease, Coccidiodomycosis, Cryptococcosis, Cytomegalovirus retinus, encephalopathy, Herpes Simplex Virus, Histoplasmosis, Isosporiasis, Kaposi's sarcoma, Leishmaniasis, Microsporidiosis, Mycobacterium avium complex, mycobacterium (non-tuberculous), Nocardiosis, Pneumocystis carinii pneumonia, Pneumonia, Progressive Multifocal Leukoencephalopathy, Rhodococcus equi, Salmonella, Toxoplasmosis, Wasting. Number of cases (no time-to analysis was performed due to small numbers).

    Time frame: baseline to week 48

  25. Change in CD4+ Cell Count From Baseline to Week 2.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 2

  26. Change in CD4+ Cell Count From Baseline to Week 4.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 4

  27. Change in CD4+ Cell Count From Baseline to Week 6.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 6

  28. Change in CD4+ Cell Count From Baseline to Week 8.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 8

  29. Change in CD4+ Cell Count From Baseline to Week 12.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 12

  30. Change in CD4+ Cell Count From Baseline to Week 24.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 24

  31. Change in CD4+ Cell Count From Baseline to Week 36.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 36

  32. Change in CD4+ Cell Count From Baseline to Week 48.

    Patients on-treatment, data within time windows

    Time frame: baseline to week 48

  33. Change in Fasting Plasma Total Cholesterol Level

    Time frame: baseline to week 48

  34. Change in Fasting Plasma Triglycerides Level

    Time frame: baseline to week 48

  35. Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level

    Time frame: baseline to week 48

  36. Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level

    Time frame: baseline to week 48

  37. Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio

    Time frame: baseline to week 48

  38. Change in Framingham Score

    Framingham prediction of 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \[MI\] or CHD death) based on the patient's gender, age, systolic blood pressure, total cholesterol, HDL-c and smoking status. The scale for the estimated risk ranges from 0 to 30%.

    Time frame: baseline to week 48

  39. Change in Revised Framingham Score According to the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group

    Time frame: baseline to week 48

  40. Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48

    using 4-variable Modification of Diet in Renal Disease (MDRD) formula

    Time frame: baseline to week 48

  41. Percentage Adherence by Pill Count

    Number of pills not returned / number of treatment days in percent (%)

    Time frame: baseline to week 48

  42. Number of Participants With Genotypic Resistance at the Time of Virologic Failure.

    Genotypic resistance was measured by the following: Plasma samples for HIV-1 resistance were analyzed using a standard clinical assay that generates a virtual phenotypic interpretation of HIV-1 sequence data and predicts susceptibility or resistance of the isolate to approved ARVs. This analysis has not been performed.

    Time frame: baseline to week 48

  43. Incidence of Patients With AIDS Progression at Each Visit

    Cumulative incidence of patients with AIDS progression are shown

    Time frame: baseline to week 52

  44. Proportion of Patients Reporting CNS Side Effects of Any Severity

    Time frame: baseline to week 52

  45. Proportion of Patients Reporting Hepatic Events of Any Severity

    Time frame: baseline to week 52

  46. Proportion of Patients Reporting Rash of Any Severity

    Time frame: baseline to week 52

  47. Proportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities

    Time frame: baseline to week 52

07

Results

Posted May 23, 2011

Participant flow

Patients were recruited from 28 Sep 2007 through 23 Mar 2009 at 18 sites throughout the US. The sites were comprised of medical centers or private practice physicians.

Participant flow — Overall Study
MilestoneNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Started7577
Completed5159
Not completed2418
Withdrew: Adverse event99
Withdrew: Protocol violation11
Withdrew: Lost to follow-up56
Withdrew: Withdrawal by subject22
Withdrew: Lack of efficacy60
Withdrew: Other10

Outcome measures

PrimaryNumber of Participants With Virologic Response (VR)

VR is defined as HIV viral load of \<50 copies/ml measured at two consecutive visits PRIOR TO Week 48 and without subsequent rebound or change of ARV therapy prior to Week 48.

Time frame:
baseline to week 48
Reported as:
Number · participants
Number of Participants With Virologic Response (VR)
participantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Responders4650
Nonresponders2927
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · Cochran-Mantel-Haenszel · p = 0.7142 · Difference in proportion of responders: -0.041 · 95% CI -0.183 to 0.101Controlling for screening viral load and CD4+ categories
SecondaryNumber of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm

HIV viral load \<50 copies/ml measured at two consecutive visits UP TO Week 48 and without subsequent rebound or change of ARV therapy up to Week 48.

Time frame:
baseline to week 48
Reported as:
Number · Participants
Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Responders4851
Nonresponders2726
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · Cochran-Mantel-Haenszel · p = 0.6479 · Difference in proportion of responders: -0.027 · 95% CI -0.167 to 0.113Controlling for screening viral load and CD4+ categories
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 48

HIV viral load \<50 copies/ml measured at Week 48 among observed cases on-treatment.

Time frame:
baseline to week 48
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Responders4248
Nonresponders28
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · Cochran-Mantel-Haenszel · p = 0.1477 · Difference in proportion of responders: 0.084 · 95% CI -0.030 to 0.197Controlling for screening viral load and CD4+ categories
SecondaryNumber of Participants With Virologic Success (FDA Definition)

HIV viral load \<50 copies/ml measured in the Week 48 window whereby patients withdrawing early and patients without a Week 48 assessment are considered failures. Includes all participants in full analysis set (FAS).

Time frame:
baseline to week 48
Reported as:
Number · Participants
Number of Participants With Virologic Success (FDA Definition)
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Responders4248
Nonresponders3329
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · Cochran-Mantel-Haenszel · p = 0.3703 · Difference in proportion of responders: -0.067 · 95% CI -0.215 to 0.080Controlling for screening viral load and CD4+ categories
SecondaryTime to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants

Time to response whereby patients withdrawing early were censored after their withdrawal

Time frame:
baseline to week 48
Reported as:
Median · days
Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants
daysNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants57 (42 to 168)84 (56 to 173)
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · Regression, Cox · p = 0.0314 · Hazard ratio (hr): 0.666 · 95% CI 0.460 to 0.964Controlling for screening viral load and CD4+ categories.
SecondaryTime to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml
Time frame:
baseline to week 48
Reported as:
Median · days
Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml
daysNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml55 (41 to 85)84 (56 to 169)
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · Regression, Cox · p = 0.0172 · Hazard ratio (hr): 0.628 · 95% CI 0.428 to 0.921Controlling for screening viral load and CD4+ categories
SecondaryNumber of Participants With Loss of Virologic Response Following Confirmed Virologic Response

HIV viral load \> 50 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)

Time frame:
baseline to week 24 and week 48
Reported as:
Number · Participants
Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
At week 2414
At week 4829
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 2
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml65
HIV viral load ≥ 50 copies/ml6263
Missing data79
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 4
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml1210
HIV viral load ≥ 50 copies/ml5362
Missing data105
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 6
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml2314
HIV viral load ≥ 50 copies/ml3853
Missing data1410
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 8
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml3423
HIV viral load ≥ 50 copies/ml2550
Missing data164
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 12
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml4243
HIV viral load ≥ 50 copies/ml2027
Missing data137
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 24
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml4861
HIV viral load ≥ 50 copies/ml95
Missing data1811
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 36
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml5355
HIV viral load ≥ 50 copies/ml45
Missing data1817
SecondaryNumber of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 48
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 50 copies/ml4248
HIV viral load ≥ 50 copies/ml28
Missing data3121
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 2
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml2417
HIV viral load ≥ 400 copies/ml4451
Missing data79
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 4
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml3831
HIV viral load ≥ 400 copies/ml2741
Missing data105
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 6
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml4044
HIV viral load ≥ 400 copies/ml2123
Missing data1410
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 8
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml4858
HIV viral load ≥ 400 copies/ml1115
Missing data164
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 12
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml5663
HIV viral load ≥ 400 copies/ml67
Missing data137
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 24
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml5163
HIV viral load ≥ 400 copies/ml63
Missing data1811
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 36
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml5459
HIV viral load ≥ 400 copies/ml31
Missing data1817
SecondaryNumber of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment

Results within time windows, patients on-treatment

Time frame:
baseline to week 48
Reported as:
Number · Participants
Number of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
HIV viral load < 400 copies/ml4354
HIV viral load ≥ 400 copies/ml12
Missing data3121
SecondaryNumber of Patients With Virologic Rebound to >400 Copies/ml

HIV viral load \>400 copies/ml on two consecutive measurements separated by at least 2 weeks, after confirmed virologic response (2 consecutive HIV viral load values \< 50 copies/ml)

Time frame:
baseline to week 48
Reported as:
Number · Participants
Number of Patients With Virologic Rebound to >400 Copies/ml
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Rebound following response26
No rebound following response5563
SecondaryAIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death

AIDS defining illnesses include: Aspergillosis, Bartonellosis, Candidiasis, Cervical cancer, Chagas disease, Coccidiodomycosis, Cryptococcosis, Cytomegalovirus retinus, encephalopathy, Herpes Simplex Virus, Histoplasmosis, Isosporiasis, Kaposi's sarcoma, Leishmaniasis, Microsporidiosis, Mycobacterium avium complex, mycobacterium (non-tuberculous), Nocardiosis, Pneumocystis carinii pneumonia, Pneumonia, Progressive Multifocal Leukoencephalopathy, Rhodococcus equi, Salmonella, Toxoplasmosis, Wasting. Number of cases (no time-to analysis was performed due to small numbers).

Time frame:
baseline to week 48
Reported as:
Number · Participants
AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death
ParticipantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death13
SecondaryChange in CD4+ Cell Count From Baseline to Week 2.

Patients on-treatment, data within time windows

Time frame:
baseline to week 2
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 2.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 2.62.6 ± 80.961.0 ± 69.7
SecondaryChange in CD4+ Cell Count From Baseline to Week 4.

Patients on-treatment, data within time windows

Time frame:
baseline to week 4
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 4.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 4.76.4 ± 88.263.0 ± 72.6
SecondaryChange in CD4+ Cell Count From Baseline to Week 6.

Patients on-treatment, data within time windows

Time frame:
baseline to week 6
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 6.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 6.87.2 ± 86.078.4 ± 67.6
SecondaryChange in CD4+ Cell Count From Baseline to Week 8.

Patients on-treatment, data within time windows

Time frame:
baseline to week 8
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 8.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 8.111.9 ± 100.290.5 ± 85.2
SecondaryChange in CD4+ Cell Count From Baseline to Week 12.

Patients on-treatment, data within time windows

Time frame:
baseline to week 12
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 12.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 12.123.1 ± 109.5102.2 ± 103.9
SecondaryChange in CD4+ Cell Count From Baseline to Week 24.

Patients on-treatment, data within time windows

Time frame:
baseline to week 24
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 24.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 24.131.8 ± 115.5132.5 ± 86.8
SecondaryChange in CD4+ Cell Count From Baseline to Week 36.

Patients on-treatment, data within time windows

Time frame:
baseline to week 36
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 36.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 36.147.6 ± 120.7120.5 ± 99.4
SecondaryChange in CD4+ Cell Count From Baseline to Week 48.

Patients on-treatment, data within time windows

Time frame:
baseline to week 48
Reported as:
Mean · cells/mm^3
Change in CD4+ Cell Count From Baseline to Week 48.
cells/mm^3Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in CD4+ Cell Count From Baseline to Week 48.155.1 ± 118.8160.4 ± 108.7
SecondaryChange in Fasting Plasma Total Cholesterol Level
Time frame:
baseline to week 48
Reported as:
Mean · mg/dl
Change in Fasting Plasma Total Cholesterol Level
mg/dlNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in Fasting Plasma Total Cholesterol Level18.2 ± 26.513.8 ± 39.5
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · ANCOVA · p = 0.7315 · Median difference (final values): 1.8 · 95% CI -8.4 to 11.9Controlling for screening viral load and CD4+ categories
SecondaryChange in Fasting Plasma Triglycerides Level
Time frame:
baseline to week 48
Reported as:
Mean · mg/dl
Change in Fasting Plasma Triglycerides Level
mg/dlNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in Fasting Plasma Triglycerides Level-4.7 ± 87.68.4 ± 120.4
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · ANCOVA · p = 0.3625 · Median difference (final values): -10.6 · 95% CI -33.4 to 12.3Controlling for screening viral load and CD4+ categories
SecondaryChange in Fasting High Density Lipoprotein (HDL) Cholesterol Level
Time frame:
baseline to week 48
Reported as:
Mean · mg/dl
Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level
mg/dlNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level9.6 ± 11.83.5 ± 15.0
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · ANCOVA · p = 0.0164 · Mean difference (final values): 4.8 · 95% CI 0.9 to 8.8Controlling for screening viral load and CD4+ categories
SecondaryChange in Fasting Low Density Lipoprotein (LDL)Cholesterol Level
Time frame:
baseline to week 48
Reported as:
Mean · mg/dl
Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level
mg/dlNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level8.7 ± 21.56.9 ± 32.2
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · ANCOVA · p = 0.9257 · Mean difference (final values): 0.4 · 95% CI -8.4 to 9.3Controlling for screening viral load and CD4+ categories
SecondaryChange in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio
Time frame:
baseline to week 48
Reported as:
Mean · ratio
Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio
ratioNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio-0.38 ± 0.96-0.02 ± 1.06
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · ANCOVA · p = 0.0375 · Mean difference (final values): -0.33 · 95% CI -0.64 to -0.02Controlling for screening viral load and CD4+ categories
SecondaryChange in Framingham Score

Framingham prediction of 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \[MI\] or CHD death) based on the patient's gender, age, systolic blood pressure, total cholesterol, HDL-c and smoking status. The scale for the estimated risk ranges from 0 to 30%.

Time frame:
baseline to week 48
Reported as:
Mean · percent 10-year risk
Change in Framingham Score
percent 10-year riskNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in Framingham Score-0.09 ± 2.010.14 ± 2.66
Statistical analysis
  • Nevirapine (NVP) Plus Truvada vs Atazanavir Plus Ritonavir (ATV/r) Plus Truvada · ANCOVA · p = 0.4645 · Mean difference (final values): -0.28 · 95% CI -1.02 to 0.47Controlling for screening viral load and CD4+ categories
SecondaryChange in Revised Framingham Score According to the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
Time frame:
baseline to week 48

No measurements were reported for this outcome.

SecondaryChange in Glomerular Filtration Rate (GFR) From Baseline to Week 48

using 4-variable Modification of Diet in Renal Disease (MDRD) formula

Time frame:
baseline to week 48
Reported as:
Mean · ml/min/1.73m^2
Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48
ml/min/1.73m^2Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48-0.06 ± 33.90-12.81 ± 35.61
SecondaryPercentage Adherence by Pill Count

Number of pills not returned / number of treatment days in percent (%)

Time frame:
baseline to week 48
Reported as:
Mean · percentage adherence
Percentage Adherence by Pill Count
percentage adherenceNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Percentage Adherence by Pill Count94.3 ± 17.797.0 ± 8.1
SecondaryNumber of Participants With Genotypic Resistance at the Time of Virologic Failure.

Genotypic resistance was measured by the following: Plasma samples for HIV-1 resistance were analyzed using a standard clinical assay that generates a virtual phenotypic interpretation of HIV-1 sequence data and predicts susceptibility or resistance of the isolate to approved ARVs. This analysis has not been performed.

Time frame:
baseline to week 48

No measurements were reported for this outcome.

SecondaryIncidence of Patients With AIDS Progression at Each Visit

Cumulative incidence of patients with AIDS progression are shown

Time frame:
baseline to week 52
Reported as:
Number · participants
Incidence of Patients With AIDS Progression at Each Visit
participantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
week 000
week 200
week 400
week 601
week 801
week 1202
week 2403
week 3603
week 4813
week 5013
End of Study Visit23
SecondaryProportion of Patients Reporting CNS Side Effects of Any Severity
Time frame:
baseline to week 52
Reported as:
Number · participants
Proportion of Patients Reporting CNS Side Effects of Any Severity
participantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Proportion of Patients Reporting CNS Side Effects of Any Severity2523
SecondaryProportion of Patients Reporting Hepatic Events of Any Severity
Time frame:
baseline to week 52
Reported as:
Number · participants
Proportion of Patients Reporting Hepatic Events of Any Severity
participantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Proportion of Patients Reporting Hepatic Events of Any Severity524
SecondaryProportion of Patients Reporting Rash of Any Severity
Time frame:
baseline to week 52
Reported as:
Number · participants
Proportion of Patients Reporting Rash of Any Severity
participantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Proportion of Patients Reporting Rash of Any Severity2119
SecondaryProportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities
Time frame:
baseline to week 52
Reported as:
Number · participants
Proportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities
participantsNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Grade 2 moderate2531
Grade 3 severe87
Grade 4 potential lifethreatening73

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nevirapine (NVP) Plus Truvada—10/75 (13.3%)50/75 (66.7%)
Atazanavir Plus Ritonavir (ATV/r) Plus Truvada—7/77 (9.1%)61/77 (79.2%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Suicidal ideationPsychiatric disorders1/752/77
Suicide attemptPsychiatric disorders0/752/77
BronchopneumoniaInfections and infestations1/750/77
Cerebral toxoplasmosisInfections and infestations1/750/77
Gastroenteritis viralInfections and infestations1/750/77
Drug hypersensitivityImmune system disorders1/750/77
Immune reconstitution syndromeImmune system disorders1/750/77
Completed suicidePsychiatric disorders1/750/77
Mononeuropathy multiplexNervous system disorders1/750/77
DizzinessNervous system disorders1/750/77
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus Truvada
Upper respiratory tract infectionInfections and infestations8/7518/77
DiarrhoeaGastrointestinal disorders12/7515/77
FatigueGeneral disorders13/7510/77
JaundiceHepatobiliary disorders0/7512/77
HeadacheNervous system disorders11/7511/77
Ocular icterusEye disorders1/7511/77
NauseaGastrointestinal disorders10/7511/77
CoughRespiratory, thoracic and mediastinal disorders7/758/77
RashSkin and subcutaneous tissue disorders7/753/77
SinusitisInfections and infestations3/757/77

Baseline characteristics

Full Analysis Set (FAS)

Age, Continuous
Age, Continuous(years)Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus TruvadaTotal
Mean37.7 ± 10.435.9 ± 9.736.8 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus TruvadaTotal
Female10616
Male6571136
Log10 HIV viral load
Log10 HIV viral load(copies/mL)Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus TruvadaTotal
Mean4.9 ± 0.84.9 ± 0.74.9 ± 0.8
CD4+ count
CD4+ count(cells/mm^3)Nevirapine (NVP) Plus TruvadaAtazanavir Plus Ritonavir (ATV/r) Plus TruvadaTotal
Mean178.9 ± 105.3183.5 ± 111.3181.2 ± 108.0
08

Study locations

19 sites
  • 1100.1512.28 Boehringer Ingelheim Investigational Site
    Beverly Hills, California, United States
  • 1100.1512.20 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 1100.1512.15 Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • 1100.1512.26 Boehringer Ingelheim Investigational Site
    Washington, District of Columbia, United States
  • 1100.1512.17 Boehringer Ingelheim Investigational Site
    Fort Lauderdale, Florida, United States
  • 1100.1512.14 Boehringer Ingelheim Investigational Site
    Orlando, Florida, United States
  • 1100.1512.23 Boehringer Ingelheim Investigational Site
    Vero Beach, Florida, United States
  • 1100.1512.29 Boehringer Ingelheim Investigational Site
    Maywood, Illinois, United States
  • 1100.1512.11 Boehringer Ingelheim Investigational Site
    Neptune, New Jersey, United States
  • 1100.1512.25 Boehringer Ingelheim Investigational Site
    Newark, New Jersey, United States
  • 1100.1512.18 Boehringer Ingelheim Investigational Site
    Somers Point, New Jersey, United States
  • 1100.1512.22 Boehringer Ingelheim Investigational Site
    Winston-Salem, North Carolina, United States
  • 1100.1512.21 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 1100.1512.13 Boehringer Ingelheim Investigational Site
    Charleston, South Carolina, United States
  • 1100.1512.30 Boehringer Ingelheim Investigational Site
    Dallas, Texas, United States
  • 1100.1512.19 Boehringer Ingelheim Investigational Site
    Fort Worth, Texas, United States
  • 1100.1512.16 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1100.1512.24 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1100.1512.27 Boehringer Ingelheim Investigational Site
    Annandale, Virginia, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007 and a primary completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2007
First posted
Nov 1, 2007
Start
Sep 2007
Primary completionActual
Mar 2010
Results first posted
May 23, 2011
Last update
Jan 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00552240
First posted
Nov 1, 2007
Start date
Sep 2007
Primary completion
Mar 2010
Results posted
May 23, 2011
Last update
Jan 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nevirapine · Atazanavir · Ritonavir

Start the discussion